Entrectinib (Rozlytrek®) - Lung Cancer
Entrectinib (Rozlytrek®) as monotherapy for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer not previously treated with ROS1 inhibitors is reimbursed on the High Tech Arrangement. A Managed Access Protocol (MAP) is in place for entrectinib for the treatment of ROS1-positive non-small cell lung cancer from 1st October 2024. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of entrectinib for the treatment of ROS1-positive non-small cell lung cancer under the High Tech Arrangement.
Applications for reimbursement approval for entrectinib for the treatment of ROS1-positive non-small cell lung cancer under the High Tech Arrangement will only be considered from consultant medical oncologists registered with the Irish Medical Council who have agreed to the terms of this MAP and been approved by the HSE. The approved consultant must submit an application for individual reimbursement approval for each patient.
A copy of the MAP for entrectinib and the application form for individual reimbursement approval can be found in the Related Files section below.
For further information, please contact mmp@hse.ie.